Skip to main content
OpenTrials
Completed

NCT Number: NCT07771556

7-Day Caffeine and Upper-Body Power in Active Women

This study investigated the effects of a 7-day caffeine supplementation on heart rate variability, cognitive performance, and upper-body anaerobic power in active women. Thirty healthy active women aged 25-30 years participated in this double-blind, placebo-controlled trial. Participants were randomly assigned to receive either 5 mg/kg of caffeine or a placebo daily for 7 days. Heart rate variability, cognitive function (measured by the Stroop test), and upper-body anaerobic power (measured by a 20-second Wingate test) were assessed at baseline, 90 minutes after supplementation, and 30 minutes after exercise. The primary outcome was peak anaerobic power. The study aimed to determine whether short-term caffeine habituation enhances exercise performance without altering cardiac autonomic function or cognitive performance.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–30 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Faculty of Sport Sciences, University of Birjand

Birjand, South Khorasan Province, 9717434765, Iran

About this study

This was a double-blind, placebo-controlled, parallel-group study conducted at the University of Birjand, Iran. Thirty active women (aged 25-30 years, BMI 18-25 kg/m²) were randomly assigned to either a caffeine group (n=15) or a placebo group (n=15). Participants received 5 mg/kg of caffeine powder or placebo (flour) in gelatin capsules daily for 7 days.

Heart rate variability (HRV) parameters including RMSSD (Root Mean Square of Successive Differences), SDNN (Standard Deviation of Normal-to-Normal Intervals), LF (Low-Frequency) power, HF (High-Frequency) power, and LF/HF ratio were measured using a Polar H10 heart rate sensor. Cognitive performance was assessed using the Golden Stroop Test (color-word interference task). Upper-body anaerobic power was measured using a 20-second Wingate test on a cycle ergometer (Monark 891 E) with a workload of 50 g/kg body weight.

Measurements were taken at three time points: baseline (after 10-hour overnight fast), 90 minutes post-ingestion, and 30 minutes post-exercise. The protocol was repeated after 7 days of daily supplementation. Data were analyzed using repeated-measures ANOVA with Bonferroni post-hoc tests. The primary outcome was peak power output (W·kg-¹) during the Wingate test. Secondary outcomes included HRV parameters, cognitive performance scores, and other anaerobic performance indices (mean power, minimum power, fatigue index).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Active women aged 25 to 30 years

Body mass index (BMI) between 18 and 25 kg/m²

Physical activity readiness (based on the PAR-Q questionnaire)

No injuries within the last month

Non-smoking

No cold or COVID-19 infection in the past four weeks

No cardiovascular, metabolic, or respiratory infections in the last three months

Normal blood pressure

No use of anabolic steroids, central nervous system stimulants, or other sports supplements in the past six months

Exclusion criteria

Inability to follow the protocol

Daily caffeine intake exceeding 300 mg (assessed using an adapted FFQ)

Consumption of alcohol or intense aerobic activity within 48 hours prior to testing

Resistance training with weights within 72 hours prior to testing

Caffeine consumption within 24 hours prior to testing

Treatment and study plan

Caffeine

Dietary Supplement

5 mg/kg of body weight of caffeine powder in a gelatin capsule, ingested daily for 7 days.

Placebo

Dietary Supplement

Matching placebo capsule containing flour, ingested daily for 7 days.

Primary outcomes

  1. Change in Upper-Body Peak Anaerobic Power

    Time frame: Measured 90 minutes post-ingestion on Day 1 and Day 7.

    Peak power output (W·kg-¹) measured during a 20-second upper-body Wingate test on a cycle ergometer (Monark 891 E).

Secondary outcomes

  1. Change in Cognitive Performance

    Time frame: Measured at baseline, 90 minutes post-ingestion, and 30 minutes post-exercise on Day 1 and Day 7.

    Cognitive performance assessed using the Golden Stroop Test (color-word interference task). The score represents the number of correct responses in the third part of the test (incongruent condition) within 45 seconds.

  2. Change in RMSSD

    Time frame: Measured at baseline, 90 minutes post-ingestion, and 30 minutes post-exercise on Day 1 and Day 7.

    Root mean square of successive differences (ms) measured using a Polar H10 heart rate sensor.

  3. Change in SDNN

    Time frame: Measured at baseline, 90 minutes post-ingestion, and 30 minutes post-exercise on Day 1 and Day 7.

    Standard deviation of normal-to-normal intervals (ms) measured using a Polar H10 heart rate sensor.

  4. Change in LF Power

    Time frame: Measured at baseline, 90 minutes post-ingestion, and 30 minutes post-exercise on Day 1 and Day 7.

    Low-frequency power (ms²) measured using a Polar H10 heart rate sensor.

  5. Change in HF Power

    Time frame: Measured at baseline, 90 minutes post-ingestion, and 30 minutes post-exercise on Day 1 and Day 7.

    High-frequency power (ms²) measured using a Polar H10 heart rate sensor.

  6. Change in LF/HF Ratio

    Time frame: Measured at baseline, 90 minutes post-ingestion, and 30 minutes post-exercise on Day 1 and Day 7.

    Ratio of low-frequency to high-frequency power (dimensionless) measured using a Polar H10 heart rate sensor.

  7. Change in Total Power (TP)

    Time frame: Measured at baseline, 90 minutes post-ingestion, and 30 minutes post-exercise on Day 1 and Day 7.

    Total power (ms²) measured using a Polar H10 heart rate sensor.

Sponsors and collaborators

Lead sponsor

Birjand University of Medical Sciences

Other

Registry information

Official study title

Seven-Day Caffeine Supplementation Enhances Upper-Body Peak Anaerobic Power Without Altering Cardiac Autonomic Function or Cognitive Performance in Active Women: A Double-Blind, Placebo-Controlled Trial

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Aug 18, 2026
Registry last updated
Aug 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.